Renalytix AI (RNLX) Stock
RNLX is no longer traded. Renalytix AI was delisted from the Nasdaq in December 2024.
Prices on this page are historical; the last trade was December 9, 2024 at $0.14.
Renalytix AI stock price history
RNLX final trading statistics
- Final close
- $0.14
- Final trading day
- Dec 9, 2024
- Market cap at delisting
- $11.78M
- Shares outstanding
- 82.96M
- Final 52-week range
- $0.12 – $2.40
- Avg. volume (final 3 mo.)
- 185,163
- All-time high (split-adj.)
- $34.78 · Jul 2021
- All-time low (split-adj.)
- $0.13 · Dec 2024
- Return since IPO
- -98.9%
- Beta
- 2.10
- Book value / share
- -$0.05
- Price / book
- -2.78
Renalytix AI annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $2.29M | -$33.5M | — |
| FY2023 | $3.40M | -$45.6M | -$1.80 |
| FY2022 | $2.97M | -$45.3M | -$1.85 |
| FY2021 | $1.49M | -$34.7M | — |
| FY2020 | $0.00 | -$9.2M | -$0.82 |
Last five fiscal years reported before the delisting; fiscal year ending June. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Renalytix AI
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.
Renalytix AI stock FAQ
What happened to Renalytix AI stock?
Renalytix AI stock was delisted from the Nasdaq. Its final close was $0.14 on December 9, 2024.
Is RNLX stock still trading?
No. RNLX was delisted from the Nasdaq in December 2024 and no longer trades on a U.S. exchange.
What was the last price of RNLX stock?
RNLX closed at $0.14 on its final trading day, December 9, 2024, for a market value of about $11.78M.
What were Renalytix AI's revenue and earnings in its last full fiscal year?
Renalytix AI reported revenue of $2.29M and net income of -$33.5M in fiscal 2024, its last full year as a public company.
When did Renalytix AI go public?
Renalytix AI stock began trading on July 17, 2020.